Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium sodium phosphosilicate is an inorganic, particulate **bioactive glass** used primarily in topical oral-care products for dentin hypersensitivity and enamel remineralization. Commonly marketed as NovaMin, the material reacts with saliva or water through ion exchange, releasing sodium, calcium, and phosphate ions and increasing local pH. This promotes deposition of a hydroxyapatite-like mineral layer on exposed dentin and enamel and physically occludes open dentinal tubules, reducing stimulus-induced fluid movement and associated sensitivity. It has been studied in dentifrices, prophylaxis pastes, powders, and dissolvable delivery systems, including clinical studies of dentin hypersensitivity, bleaching-associated tooth sensitivity, enamel demineralization, and molar-incisor hypomineralization. ([haleonhealthpartner.com](https://www.haleonhealthpartner.com/en-gb/oral-health/brands/sensodyne/science/novamin/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium sodium phosphosilicate.